Not the pop most were looking for, but also very little temptation for
the longs to compromise their positions. Three factors of descending
priority will determine the sales of Pennsaid over the next year:
marketing, price and efficacy. Covidien has already shown commitment
to NRI through bonuses and cost absorption (Pennsaid Plus Phase III),
and todays conference call superficially demonstrates a keen interest
in topical delivery for the future. Marketing Pennsaid will be a
grassroot process, and will take a concerted sales effort (unlike a
monoclonal antitumor antibody medication that is only marketed to 100
american cancer institutes) to reach the generalists. Price at this
time is unknow, but in Canada is not a factor when comparing it to
Voltaren. And finally, it is a good product with unfortunately a
potentially messy application.

I expect sales over the next three years to be acceptable, with a
robust pop when Pennsaid Plus is approved (much nicer application as a
gel). Whatever swings occur in the next few weeks is irrelevant in
lieu of the three to four year window. Hold, see a gradual and steady
rise, and look for another small pharma with potential.

On Nov 5, 8:55 am, 2011435 <si...@hotmail.com> wrote: